Interaction(s) between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals: Relevance to new therapeutic strategies in rheumatoid arthritis and other collagen vascular diseases

Prostaglandins, Leukotrienes and Essential Fatty Acids

Volumn 44, Issue 4, 1991, Pages 201-210

  Das, U N ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCITRIOL; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; ESSENTIAL FATTY ACID; FREE RADICAL; GOLD SALT; GROWTH FACTOR; HYDROXYCHLOROQUINE; ICOSANOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PENTOXIFYLLINE; PHENYLBUTAZONE; PIROXICAM; SALAZOSULFAPYRIDINE;

COLLAGEN DISEASE; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; VASCULAR DISEASE;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL RESPONSE MODIFIERS; COLLAGEN DISEASES; CYTOKINES; DISEASE SUSCEPTIBILITY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EICOSANOIDS; FATTY ACIDS, ESSENTIAL; FREE RADICALS; GENETIC PREDISPOSITION TO DISEASE; GROWTH SUBSTANCES; HLA-DR ANTIGENS; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHILS; PREVALENCE;

EID: 0025841884     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/0952-3278(91)90018-Z     Document Type: Review

References (93)

1. Rheumatoid arthritis
2. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials
3. Taking mortality in rheumatoid arthritis seriously — predictive markers, socioeconomic status and comorbidity
4. Evolving concepts of pathogenesis and therapy of rheumatoid arthritis
5. Early joint lesions of rheumatoid arthritis
6. Histopathology of the rheumatoid lesion. Identification of cell types at the sites of cartilage erosion
7. Collagenase at Sites of Cartilage Erosion in the Rheumatoid Joint
8. Transin/stromely-sin and erosion of bond and cartilage in rheumatoid arthritis and streptococcal cell wall (SCW) arthritis in LEW/N rats
9. Pathogenesis of rheumatoid arthritis
10. The immunogenetics of rheumatic diseases.
11. Gene conversion between murine Class II major histocompatibility complex loci: functional and molecular evidence from the bm 12 mutant
12. Destructive arthritis, rheumatoid factor, and HLA-DR4: susceptibility versus severity, a case control study
13. Clonal dominence among T-lymphocyte infiltrates in arthritis
14. Stimulation of neovascularization of human rheumatoid synovial tissue macrophages
15. Angiogenic factors
16. The control of antibody production by immunomodulatory molecules
17. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin-2 and interleukin-3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis
18. Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction
19. Diminished IL-2 induced gamma-interferon production by unstimulated peripheral blood lymphocytes in rheumatoid arthritis
20. 4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes
21. 5a leukotaxis in vitro and under stimulated in vivo conditions
22. Tissue injury in inflammation, oxidants, proteinases, and cationic proteins
23. 4 by neutrophils in rheumatoid arthritis
24. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions
25. Collagenolytic systems in rheumatoid arthritis
26. Transforming Growth factor-beta in rheumatoid arthritis
27. Myosin: a link between streptococci and the heart
28. Sera from patients with post streptcoccal glomerulonephritis contain antibodies to glomerular heparan sulfate proteoglycan
29. Polyspecificity of monoclonal auto-antibodies produced by human-human hybridomas
30. Sharing of antigenic determinants between the nicotinic acetylcholine receptor and proteins in Escherichia Coli, Proteus vulgaris, and klebsiella pneumoniae: possible role in the pathogenesis of myasthemia gravis
31. Autoimmunity: physiologic and pernicious
32. T lymphocytes of rheumatoid arthritis patients show augmented reactivity to a fraction of Mycobacteria cross-reactive with cartilage
33. 4-associated immune response gene for Mycobacterium tuberculosis: A clue to the pathogenesis of rheumatoid arthritis?
34. Immune complexes in rheumatoid arthritis sera and synovial fluids
35. An analysis of the levels of complement components in the synovial fluid in rheumatic diseases
36. Immune-complex activation of neutrophils and enhancement of the activation by rheumatoid factor and complement
37. Molecular analysis of complement fixing rheumatoid synovial fluid immune complexes
38. Possible role of free radical altered IgG in the aetiopathogenesis of rheumatoid arthritis
39. Interleukin-1 potentiates the development of collagen-induced arthritis in mice
40. Agranulocytosis, aplastic anemia and leukemia: Relevance to arachidonic acid metabolism
41. Activation of neutrophils by recombinant interleukin 6
42. Cytokines in chronic inflammatory arthritis
43. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis
44. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis
45. Interleukin 1 increases the production of endothelin—1 by cultured endothelial cells
46. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon
47. Interleukin-2 in scleroderma: correlation of serum levels with extent of skin involvement and disease duration
48. Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells
49. Effects of prostaglandins and c-AMP levels on monocyte IL-1 production
50. Arachidonic acid metabolites regulate interleukin-1 production
51. Release of tumor necrosis factor-alpha from macrophages
52. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumour necrosis factor by mononuclear cells
53. Prostaglandin E precursor fatty acids inhibit human IL-2 production by a PGE-independent mechanism
54. Suppression of interleukin-2 dependent human T cell growth in vitro by prostaglandin E (PGE) and their precursor fatty acids
55. Human tumor necrosis factor-alpha (TNF-alpha) directly stimulates arachidonic acid release in human neutrophils
56. Tumor necrosis factor provokes superoxide anion generation from neutrophils
57. Stimulation of free radical generation in human leukocytes by various stimulants including tumor necrosis factor is a calmodulin dependent process
58. 2
59. Lipoxygenase inhibitors suppress formation of tumor necrosis factor in vitro and in vivo
60. Reduced tumor necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism
61. Gamma-linolenic acid, arachidonic acid and eicosapentaenoic acid as potential anti-cancer drugs
62. Characteristics of tumor necrosis factor production in rheumatoid arthritis
63. Free radicals as possible mediators of the actions of interferon
64. Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin production in rheumatoid arthritis
65. Dexamethasone and pentoxyfylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at seperate points in the signalling pathway
66. 3
67. 3
68. The transforming growth factor-betas
69. Some recent advances in the chemistry and biology of transforming growth factor-beta
70. Transforming growth factor-beta is a potent inhibitor of IL-1, induced protease activity and cartilage proteoglycan degradation
71. Transforming growth factor-beta modulates the expression of collagenase and metalloproteinase inhibitor
72. Transcriptional modulation of transforming growth factor-beta
73. Transforming growth factor-beta stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular chondrocytes
74. Transforming growth factor-beta in rheumatoid arthrits
75. Observations in the potential role of transforming growth factor-beta in cutaneous fibrosis. Systemic Sclerosis
76. Transforming growth factor-beta: Selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis
77. Effect of fish oil supplementatin on erythrocyte lipid pattern, malondialdehyde production, and glutathione peroxidase activity in psoriasis
78. Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis
79. Suppression of monosodium urate crystal-induced acute inflammation by diets enriched with gamma-linolenic acid and eicosapentaenoic acid
80. Dietary fatty acids and inflammatory skin disease
81. Meta-analysis of placebo-controlled studies of the efficiacy of Epogam in the treatment of atopic eczema. Relationship between plasma essential fatty acid changes and clinical response
82. Effects of altering dietary essential fatty acids on requirements for non-steriodal anti-inflammatory drugs in patients with rheumatoid arthritis. A double blind plecebo controlled study
83. Correlation of fatty acid composition of adipose tissue lipids and serum phosphatidylcholine and serum concentrations of micronutrients with disease duration in rheumatoid arthritis.
84. Prostaglandins and their precursors can modify genetic damage induced by gamma-radiation and benzo(a)pyrene
85. Prostaglandins can modify gamma-radiation and chemical-induced cytotoxicity and genetic damage in vitro and in vivo
86. The regulation of prostaglandin biosynthesis. Negative feedback mechanisms and the selective control of formation of 1 and 2 series prostaglandins: Relevance to inflammation and immunity
87. Cyclosporin A suppresses the expression of the interleukin-2 gene by inhibiting the binding of lymphocyte-specific factors to the IL-2 enhancer
88. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis
89. Effects of low dose corticosteriods on bone mass in rheumatoid arthritis: A longitudinal study
90. Non-A, Non-B Hepatitis: Sorting through a Diagnosis of Exclusion
91. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1